Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

NCT ID: NCT00373568

Last Updated: 2010-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leishmaniasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

miltefosine: 2.5 mg/kg/day for 42 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mucosal leishmaniasis

Exclusion Criteria

* No comcomitant disease as judged by laboratory and clinical parameters
Minimum Eligible Age

12 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AB Foundation

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jaime Soto, MD

Role: PRINCIPAL_INVESTIGATOR

CIBIC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Palos Blancos

Palos Blancos, , Bolivia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bolivia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

05--01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Miltefosine for Brazilian Visceral Leishmaniasis
NCT00378495 TERMINATED PHASE1/PHASE2
Treatment of Mucosal Bolivian Leishmaniasis
NCT04799236 RECRUITING PHASE3